Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00882245
Recruitment Status : Completed
First Posted : April 16, 2009
Last Update Posted : October 30, 2009
Information provided by:
Serentis Ltd.

Brief Summary:
Atopic Dermatitis is a chronic inflammatory skin disease that affect 10 to 15% of children and 2 to 10% of adults. AD is characterised by an itchy skin eruption and may cover large parts of the body. The exact cause is unknown but is thought to be an interplay between genetic and and environmental factors. The objective of this study is to determine whether SRD441 ointment is a safe and effective therapy for mild to moderate Atopic Dermatitis.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Other: Vehicle ointment Drug: Ointment Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-Blind, Vehicle Controlled Study to Determine the Efficacy, Safety and Toleration of SRD441 Ointment in Patients With Atopic Dermatitis
Study Start Date : April 2009
Actual Primary Completion Date : August 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Placebo Comparator: Vehicle ointment Other: Vehicle ointment
Topical vehicle cream

Experimental: SRD441 Ointment Drug: Ointment
SRD441 Ointment

Primary Outcome Measures :
  1. Measure efficacy in treating acute exacerbations [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Safety and local dermal tolerability [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects aged 18 or over
  • Subjects with a history of AD
  • Written and dated informed consent
  • Satisfactory medical assessment with no clinical relevant abnormalities.

Exclusion Criteria:

  • Subjects with current or recurrent disease (except AD) that could affect the site of application, the action, absorption or disposition of the investigational product, or clinical or laboratory assessments.
  • Subjects who have medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
  • Subjects with any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive UV exposure, at the possible drug application sites which could impact the application of the test agent or confound the local assessments during this study.
  • Subjects with clinically significant renal and liver parameters, as defined as greater than 1.5 x creatinine and 3 x AST ULN (upper limit of normal) respectively.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00882245

Layout table for location information
Plovdiv, Bulgaria
Sofia, Bulgaria
Helsinki, Finland
Berlin, Germany
Bonn, Germany
Cologne, Germany
Frankfurt, Germany
Hannover, Germany
Heidelberg, Germany
Kiel, Germany
Munich, Germany
Munster, Germany
Sponsors and Collaborators
Serentis Ltd.
Layout table for investigator information
Study Director: Robert Tansley Serentis Ltd.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Robert Tansley, Chief Medical Officer, Serentis Ltd Identifier: NCT00882245    
Other Study ID Numbers: P441201CD
First Posted: April 16, 2009    Key Record Dates
Last Update Posted: October 30, 2009
Last Verified: October 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases